Tradestie Institutional Equity Comparison Engine

ACHV vs CGEN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CGEN Overall Edge

CGEN Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Compugen Ltd (CGEN) driven by superior Valuation, Growth & Margin while ACHV counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, ACHV trades at 35.3x Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus CGEN at 12.4x Forward P/E and 41.3% operating margin (+102.1% YoY). In options structure, ACHV sits in BREAKOUT (23rd %ile IV; Dealer Gamma Walls on Pro) against CGEN sits in BREAKDOWN (57th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CGEN
ACHV 35.3x vs CGEN 12.4x Fwd P/E
Growth & Margin Winner CGEN
Op Margin 0.0% vs 41.3% ยท YoY +0.0% vs +102.1%
Momentum & Technical Winner ACHV
1Y +43.0% vs +23.2% ยท 52W Pos 69% vs 33%
Options & Structure Winner ACHV
BREAKOUT (23rd %ile IV) vs BREAKDOWN (57th %ile IV)
ACHV NASDAQ
Achieve Life Sciences, Inc.
In Vitro & In Vivo Diagnostic Substances
$6.78
+0.89% 1D
Market Cap $692.8M
1M Return -8.5%
1Y Return +43.04%
Forward P/E 35.3x
Unified AI Score
56.6 / 100 HOLD
Tech 66.0 Fund 58.0 Flow 57.0 Mom 58.9
CGEN NASDAQ
Compugen Ltd
Biological Products, (No Diagnostic Substances)
$2.02
-0.98% 1D
Market Cap $193.2M
1M Return +2.54%
1Y Return +23.17%
Forward P/E 12.4x
Unified AI Score
49.8 / 100 HOLD
Tech 53.0 Fund 52.0 Flow 55.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ACHV +43.04% CGEN +23.17% Spread: +24.3 pp (ACHV Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ACHV TTM Op. Margin: 0.0% CGEN TTM Op. Margin: 41.3%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACHV vs CGEN. Trailing 12-month operating profitability (ACHV 0.0% vs CGEN 41.3%) and valuation multiples (ACHV 35.3x vs CGEN 12.4x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ACHV (3) vs CGEN (6)
Institutional Metric ACHV CGEN Criterion Row Winner
Market Capitalization Scale $692.8M $193.2M Larger Scale ACHV
Trailing P/E Ratio Valuation 35.3x 5.2x Lower Multiple CGEN
Forward P/E Ratio Valuation 35.3x 12.4x Lower Multiple CGEN
Revenue Growth (YoY) Growth +0.0% +102.1% Higher Growth CGEN
Operating Margin (TTM) Profitability 0.0% 41.3% Higher Margin CGEN
Net Profit Margin Profitability 0.0% 47.9% Higher Margin CGEN
Return on Equity (ROE) Capital Efficiency -845.0% 57.2% Higher ROE CGEN
52-Week Range Position Momentum 69% ($3โ€“$9) 33% ($1โ€“$3) Stronger Trend ACHV
Beta / 30D Volatility Risk Regime 1.73ฮฒ ยท 62% Vol 1.44ฮฒ ยท 62% Vol Lower Realized Risk Tie
Unified Institutional Score Composite Signal 56.6 / 100 (HOLD) 49.8 / 100 (HOLD) Higher Composite ACHV

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ACHV vs CGEN Buy Guide
ACHV BREAKOUT
125d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 23rd %ile
IV Regime Compressed (<25th %ile)
Live ACHV Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CGEN BREAKDOWN
143d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 57th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CGEN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ACHV nor CGEN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.